AnaptysBio (ANAB) Price Target Raised to $145.00 at Jefferies Group

AnaptysBio (NASDAQ:ANAB) had its price objective increased by equities researchers at Jefferies Group from $6.59 to $145.00 in a report issued on Monday, February 19th, The Fly reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Jefferies Group’s target price would suggest a potential upside of 24.82% from the stock’s previous close. Jefferies Group also issued estimates for AnaptysBio’s FY2021 earnings at ($5.67) EPS and FY2022 earnings at ($0.80) EPS.

Several other research firms have also commented on ANAB. SunTrust Banks lifted their price target on AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. ValuEngine upgraded AnaptysBio from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Credit Suisse Group set a $135.00 price target on AnaptysBio and gave the company an “outperform” rating in a report on Tuesday, January 23rd. Robert W. Baird reissued a “buy” rating and issued a $144.00 price objective (up previously from $81.00) on shares of AnaptysBio in a research note on Friday, January 19th. Finally, Zacks Investment Research downgraded AnaptysBio from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $129.67.

AnaptysBio (NASDAQ ANAB) traded up $2.75 during mid-day trading on Monday, reaching $116.17. The company had a trading volume of 354,461 shares, compared to its average volume of 293,516. The company has a current ratio of 17.93, a quick ratio of 17.93 and a debt-to-equity ratio of 0.02. AnaptysBio has a one year low of $18.15 and a one year high of $134.00. The company has a market cap of $2,697.66, a price-to-earnings ratio of -71.27 and a beta of 1.94.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.12. The firm had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $0.89 million. The business’s quarterly revenue was up 9.1% on a year-over-year basis. equities research analysts predict that AnaptysBio will post -2.3 earnings per share for the current year.

Several large investors have recently bought and sold shares of ANAB. Evercore Wealth Management LLC purchased a new position in shares of AnaptysBio during the 3rd quarter worth approximately $100,000. Legal & General Group Plc boosted its position in AnaptysBio by 160.8% in the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 1,951 shares during the period. New York State Common Retirement Fund purchased a new position in AnaptysBio in the 2nd quarter valued at approximately $168,000. Nationwide Fund Advisors boosted its position in AnaptysBio by 89.5% in the 3rd quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 2,776 shares during the period. Finally, Two Sigma Securities LLC purchased a new position in AnaptysBio in the 4th quarter valued at approximately $212,000. 99.25% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “AnaptysBio (ANAB) Price Target Raised to $145.00 at Jefferies Group” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

The Fly

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with's FREE daily email newsletter.

Leave a Reply